SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mimedx Group, Inc. – ‘10-K’ for 12/31/13 – ‘R32’

On:  Tuesday, 3/4/14, at 4:11pm ET   ·   For:  12/31/13   ·   Accession #:  1376339-14-5   ·   File #:  1-35887

Previous ‘10-K’:  ‘10-K’ on 3/15/13 for 12/31/12   ·   Next:  ‘10-K/A’ on 4/30/14 for 12/31/13   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/04/14  Mimedx Group, Inc.                10-K       12/31/13   81:10M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    790K 
 2: EX-10.3     Material Contract                                   HTML     33K 
 3: EX-10.4     Material Contract                                   HTML     32K 
 4: EX-10.5     Material Contract                                   HTML     31K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     22K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     24K 
57: R1          Document and Entity Information                     HTML     50K 
46: R2          Consolidated Balance Sheets                         HTML    124K 
55: R3          Consolidated Balance Sheets (Parenthetical)         HTML     49K 
59: R4          Consolidated Statements of Operations               HTML     81K 
75: R5          Consolidated Statements of Stockholders' Equity     HTML    151K 
48: R6          Consolidated Statements of Stockholders' Equity     HTML     25K 
                (Parenthetical)                                                  
54: R7          Consolidated Statements of Cash Flows               HTML    156K 
42: R8          Consolidated Statements of Cash Flows               HTML     24K 
                (Parenthetical)                                                  
32: R9          Nature of Business                                  HTML     26K 
76: R10         Significant Accounting Policies                     HTML     62K 
61: R11         Liquidity and Management's Plans                    HTML     24K 
60: R12         Inventories                                         HTML     37K 
66: R13         Property and Equipment                              HTML     41K 
67: R14         Intangible Assets and Royalty Agreement             HTML     66K 
64: R15         Long-Term Debt                                      HTML     47K 
68: R16         Net Income (loss) Per Share                         HTML     56K 
56: R17         Common Stock Placements                             HTML     38K 
58: R18         Equity                                              HTML    218K 
63: R19         Income Taxes                                        HTML     64K 
81: R20         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     69K 
                Investing and Financing Activities                               
71: R21         Related Party Transactions                          HTML     47K 
51: R22         401k Plan                                           HTML     33K 
62: R23         Commitments and Contingencies                       HTML     42K 
53: R24         Quarterly Financial Data (Unaudited)                HTML     80K 
25: R25         Schedule II - Valuation and Qualifying Accounts     HTML     57K 
                (Notes)                                                          
72: R26         Significant Accounting Policies (Policies)          HTML    157K 
78: R27         Inventories (Tables)                                HTML     35K 
37: R28         Property and Equipment (Tables)                     HTML     38K 
36: R29         Intangible Assets and Royalty Agreement (Tables)    HTML     65K 
40: R30         Long-Term Debt (Tables)                             HTML     40K 
41: R31         Net Income (loss) Per Share (Tables)                HTML     56K 
43: R32         Equity (Tables)                                     HTML    224K 
23: R33         Income Taxes (Tables)                               HTML     57K 
69: R34         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     66K 
                Investing and Financing Activities (Tables)                      
50: R35         Related Party Transactions (Tables)                 HTML     43K 
52: R36         Commitments and Contingencies (Tables)              HTML     30K 
28: R37         Quarterly Financial Data (Unaudited) (Tables)       HTML     77K 
80: R38         Nature of Business (Details)                        HTML     24K 
17: R39         Significant Accounting Policies (Details)           HTML     61K 
44: R40         Liquidity and Management's Plans (Details)          HTML     34K 
74: R41         Inventories (Details)                               HTML     40K 
27: R42         Property and Equipment (Details)                    HTML     43K 
35: R43         Intangible Assets and Royalty Agreement (Details)   HTML    132K 
39: R44         Long-Term Debt (Schedule of Debt Instruments)       HTML     37K 
                (Details)                                                        
47: R45         Long-Term Debt (Details)                            HTML     83K 
22: R46         Net Income (loss) Per Share (Details)               HTML     73K 
31: R47         Common Stock Placements (Details)                   HTML     37K 
19: R48         Equity (Narrative) (Details)                        HTML     42K 
73: R49         Equity (Activity of Stock Options) (Details)        HTML     86K 
26: R50         Equity (Exercise Price Ranges) (Details)            HTML     63K 
70: R51         Equity (Summary of Unvested Stock Options)          HTML     41K 
                (Details)                                                        
29: R52         Equity (Assumptions) (Details)                      HTML     38K 
45: R53         Equity (Summary of Restricted Stock Awards)         HTML     63K 
                (Details)                                                        
18: R54         Equity (Recognized Stock-Based Compensation)        HTML     30K 
                (Details)                                                        
21: R55         Equity (Warrants) (Details)                         HTML     71K 
38: R56         Income Taxes (Details)                              HTML     90K 
24: R57         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     93K 
                Investing and Financing Activities (Details)                     
77: R58         Related Party Transactions (Details)                HTML     36K 
49: R59         401k Plan (Details)                                 HTML     35K 
65: R60         Commitments and Contingencies (Details)             HTML     40K 
30: R61         Quarterly Financial Data (Unaudited) (Details)      HTML     43K 
33: R62         Schedule II - Valuation and Qualifying Accounts     HTML     35K 
                (Details)                                                        
79: XML         IDEA XML File -- Filing Summary                      XML    114K 
20: EXCEL       IDEA Workbook of Financial Reports                  XLSX    204K 
34: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.48M 
10: EX-101.INS  XBRL Instance -- mdxg-20131231                       XML   2.43M 
12: EX-101.CAL  XBRL Calculations -- mdxg-20131231_cal               XML    199K 
13: EX-101.DEF  XBRL Definitions -- mdxg-20131231_def                XML    511K 
14: EX-101.LAB  XBRL Labels -- mdxg-20131231_lab                     XML   1.82M 
15: EX-101.PRE  XBRL Presentations -- mdxg-20131231_pre              XML    918K 
11: EX-101.SCH  XBRL Schema -- mdxg-20131231                         XSD    178K 
16: ZIP         XBRL Zipped Folder -- 0001376339-14-000005-xbrl      Zip    249K 


‘R32’   —   Equity (Tables)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v2.4.0.8
Equity (Tables)
12 Months Ended
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock options activity
Activity with respect to the stock options is summarized as follows:
 
Number of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual
Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2013
13,614,135

 
$
1.42

 
 
 
 
Granted
4,021,000

 
$
5.31

 
 
 
 
Exercised
(1,958,674
)
 
$
1.01

 
 
 
 
Unvested options forfeited
(265,002
)
 
$
3.47

 
 
 
 
Vested options expired
(35,499
)
 
$
1.11

 
 
 
 
Outstanding at December 31, 2013
15,375,960

 
$
2.46

 
7.7
 
$
96,614,260

6,807,732

 
$
1.33

 
6.5
 
$
50,441,475

 
 
 
 
 
 
 
 
Vested or expected to vest at December 31, 2013 (a)
15,081,653

 
$
2.42

 
7.7
 
$
95,324,825

(a)
Includes forfeiture adjusted unvested shares.
Summary of stock options outstanding and exercisable
Following is a summary of stock options outstanding and exercisable at December 31,
 
 
 
2013
 
 
 
 
 
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-
Average
Remaining
Contractual
Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.50 - $0.76
1,225,935

 
4.0
 
$
0.65

 
1,225,935

 
$
0.65

$0.87 - $1.35
6,570,341

 
7.6
 
1.20

 
3,604,469

 
1.18

$1.40 - $2.29
1,571,700

 
6.1
 
1.66

 
1,321,698

 
1.66

$2.33 - $3.75
2,091,984

 
8.7
 
2.77

 
655,630

 
2.77

$3.95 - $6.02
3,435,500

 
9.3
 
5.13

 

 

$6.04 - $7.93
480,500

 
8.9
 
6.61

 

 

 
15,375,960

 
7.7
 
$
2.46

 
6,807,732

 
$
1.33

Unvested Stock Options Roll Forward
A summary of the status of the Company’s unvested stock options as of December 31 is presented below:
 
2013
 
 
Unvested Stock Options
Number of
Shares
 
Weighted-
Average
Grant Date Fair Value
Unvested at January 1, 2013
8,377,538

 
$
0.96

Granted
4,021,000

 
$
3.08

Cancelled/expired
(265,002
)
 
$
2.14

Vested
(3,565,308
)
 
$
0.94

Unvested at December 31, 2013
8,568,228

 
$
1.94

Fair value of options valuation assumptions
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:
 
Year ended December 31,
 
 
 
2013
 
2012
 
2011
Expected volatility
61.41 - 64.77%

 
45.7 - 64.3%

 
57.3-58.1%

Expected life (in years)
6

 
6

 
6

Expected dividend yield

 

 

Risk-free interest rate
0.85 - 1.88%

 
0.62 - 1.77%

 
0.86 - 2.24%

Restricted Stock Awards Roll Forward
Following is summary information for restricted stock awards for the years ended 2013 and 2012. There were no restricted stock awards in 2011 and prior years. Shares vest over a one to three year period. As of December 31, 2013, there was approximately $2,471,000 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.5 years.
 
 
Number of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at December 31, 2011
 

 

Granted
 
7,500

 
$3.49
Vested
 

 

Unvested at December 31, 2012
 
7,500

 
$3.49
Granted
 
576,550

 
$5.55
Vested
 
(2,500
)
 
$3.49
Forfeited
 
(5,000
)
 
$6.60
Unvested at December 31, 2013
 
576,550

 
$5.53
Allocation of Share-based Compensation
For the years ended December 31, 2013, 2012, and 2011 the Company recognized stock-based compensation as follows:  
 
Year Ended December 31,
 
2013
 
2012
 
2011
Cost of sales
$
279,215

 
$
97,970

 
$
98,366

Research and development
417,436

 
289,341

 
254,997

Selling, general and administrative
5,312,525

 
2,151,410

 
1,305,720

 
$
6,009,176

 
$
2,538,721

 
$
1,659,083

Summary of warrants outstanding
Common Stock warrants activity and resulting balances for the years ended December 31, 2013, 2012, and 2011 are as follows:
 
Number of
Warrants
 
Weighted-
Average
Exercise
Price per
Warrant
 
Number of
Contingent Warrants
 
Weighted-
Average
Exercise
Price per
Contingent
Warrant
Warrants outstanding at January 1, 2011
6,003,924

 
$
1.21

 
1,252,990

 
$
0.01

Issued in connection with private placement of common stock
1,889,161

 
1.50

 
1,889,162

 
0.01

Issued in connection with convertible promissory notes
203,332

 
1.50

 
203,332

 
0.01

Issued in connection with line of credit with related party

 

 
650,000

 
0.01

Issued in connection with Senior Secured Promissory Notes
1,250,000

 
0.01

 
1,250,000

 
0.01

Placement agent
42,400

 
1.09

 

 

Warrants outstanding at December 31, 2011
9,388,817

 
$
1.00

 
5,245,484

 
$
0.01

 
 
 
 
 
 
 
 
Warrants outstanding at January 1, 2012
9,388,817

 
$
1.00

 
5,245,484

 
$
0.01

Warrants issued:
 
 
 
 
 
 
 
Vested contingent warrants related to private placement of common stock
1,672,743

 
0.01

 
(1,672,743
)
 
0.01

Vested contingent warrants related to line of credit with related party
325,000

 
0.01

 
(325,000
)
 
0.01

Contingent warrants voided

 

 
(3,247,741
)
 
0.01

Warrants exercised:
 
 
 
 
 
 
 
Contingent warrants related to convertible note
(1,249,750
)
 
0.01

 

 

Contingent warrants related to private placement of common stock
(1,608,802
)
 
0.01

 

 

Contingent warrants related to line of credit with related party
(325,000
)
 
0.01

 

 

Callable warrants
(3,288,733
)
 
1.50

 

 

Other
(1,703,568
)
 
0.63

 

 

Warrants expired
(10,000
)
 
1.00

 

 

Warrants redeemed for cashless exercises
(14,789
)
 
0.53

 

 

Repurchased callable warrants
(56,750
)
 
1.50

 

 

Warrants outstanding at December 31, 2012
3,129,168

 
$
1.04

 

 
$

 
 
 
 
 
 
 
 
Warrants outstanding at January 1, 2013
3,129,168

 
1.04

 

 

Warrants exercised:
 
 
 
 
 
 
 
Other
(1,844,352
)
 
1.14

 

 

Warrants outstanding at December 31, 2013
1,284,816

 
$
0.90

 

 
$


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/4/14
For Period end:12/31/1310-K/A
1/1/13
12/31/1210-K
1/1/12
12/31/1110-K,  10-K/A
1/1/11
9/15/094
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Mimedx Group, Inc.                10-K       12/31/23  116:11M
 2/28/23  Mimedx Group, Inc.                10-K       12/31/22  123:13M
 2/28/22  Mimedx Group, Inc.                10-K       12/31/21  112:13M
 3/08/21  Mimedx Group, Inc.                10-K       12/31/20  111:12M
Top
Filing Submission 0001376339-14-000005   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 3:22:53.2pm ET